ATE369420T1 - Kvlqt1 - im zusammenhang mit 'long qt syndrom' - Google Patents

Kvlqt1 - im zusammenhang mit 'long qt syndrom'

Info

Publication number
ATE369420T1
ATE369420T1 AT99922910T AT99922910T ATE369420T1 AT E369420 T1 ATE369420 T1 AT E369420T1 AT 99922910 T AT99922910 T AT 99922910T AT 99922910 T AT99922910 T AT 99922910T AT E369420 T1 ATE369420 T1 AT E369420T1
Authority
AT
Austria
Prior art keywords
syndrome
long
kvlqt1
disclosed
mutations
Prior art date
Application number
AT99922910T
Other languages
German (de)
English (en)
Inventor
Mark T Keating
Michael C Sanguinetti
Mark E Curran
Gregory M Landes
Timothy D Connors
Timothy C Burn
Igor Splawski
Qing Cn Wang
Original Assignee
Univ Utah Res Found
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utah Res Found, Genzyme Corp filed Critical Univ Utah Res Found
Application granted granted Critical
Publication of ATE369420T1 publication Critical patent/ATE369420T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
AT99922910T 1998-07-29 1999-05-12 Kvlqt1 - im zusammenhang mit 'long qt syndrom' ATE369420T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9447798P 1998-07-29 1998-07-29
US09/135,010 US6277978B1 (en) 1995-12-22 1998-08-17 KVLQT1—a long QT syndrome gene

Publications (1)

Publication Number Publication Date
ATE369420T1 true ATE369420T1 (de) 2007-08-15

Family

ID=26788931

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99922910T ATE369420T1 (de) 1998-07-29 1999-05-12 Kvlqt1 - im zusammenhang mit 'long qt syndrom'

Country Status (8)

Country Link
US (5) US6277978B1 (enExample)
EP (1) EP1100538B1 (enExample)
JP (1) JP2002521045A (enExample)
AT (1) ATE369420T1 (enExample)
AU (1) AU758048B2 (enExample)
CA (1) CA2336263A1 (enExample)
DE (1) DE69936781T2 (enExample)
WO (1) WO2000006199A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797486B2 (en) * 1996-09-11 2004-09-28 Icagen, Incorporated Small and intermediate conductance, calcium-activated potassium channels and uses thereof
US7179597B2 (en) 2000-04-13 2007-02-20 Georgetown University Genetic diagnosis for QT prolongation related adverse drug reactions
US6348486B1 (en) * 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
CA2457365A1 (en) * 2001-08-20 2003-02-27 Genaissance Pharmaceuticals, Inc. Polymorphisms associated with ion-channel disease
JP2006511218A (ja) * 2002-12-21 2006-04-06 ファイザー・プロダクツ・インク 薬物誘発性不整脈に関連する方法および組成物
US7537928B2 (en) * 2003-08-22 2009-05-26 Masonic Medical Research Laboratory Mutations in ion channel proteins associated with sudden cardiac death
US7833718B2 (en) * 2006-11-06 2010-11-16 Masonic Medical Research Laboratory CACNA1C nucleic acid mutations as indicators of shorter than normal QT interval and ST segment elevation associated with sudden cardiac death

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2085478A1 (en) * 1995-12-22 2009-08-05 University Of Utah Research Foundation A long QT syndrome gene which encodes KVLQT1 and its association with minK
ATE211918T1 (de) 1996-10-21 2002-02-15 Morten Sloth Weidner Pharmazeutische zusammenstellungen mit parthenium integrifolium oder mit einem extrakt oder einer komponente davon, verwendung dieses pflanzenmaterials zur herstellung von medizin und ein verfahren zur extraktherstellung von parthenium integrifolium
DK1066042T3 (da) 1998-03-26 2006-12-18 Phytopharm Plc Steroidale saponiner til behandling af Alzheimers sygdom
AUPP797598A0 (en) 1998-12-30 1999-01-28 Butters, Desley Therapeutic agent
US6194469B1 (en) 1998-12-11 2001-02-27 Board Of Trustees Operating Michigan State Univeristy Method for inhibiting cyclooxygenase and inflammation using cherry bioflavonoids
US20010006686A1 (en) 1999-03-19 2001-07-05 David G. Corley Inflammatory mediation obtained from atractylodes lancea

Also Published As

Publication number Publication date
US20030170708A1 (en) 2003-09-11
US6451534B1 (en) 2002-09-17
AU3980099A (en) 2000-02-21
WO2000006199A8 (en) 2001-04-12
US6972176B2 (en) 2005-12-06
DE69936781D1 (de) 2007-09-20
US6582913B1 (en) 2003-06-24
AU758048B2 (en) 2003-03-13
CA2336263A1 (en) 2000-02-10
DE69936781T2 (de) 2008-06-05
EP1100538B1 (en) 2007-08-08
JP2002521045A (ja) 2002-07-16
US6277978B1 (en) 2001-08-21
EP1100538A2 (en) 2001-05-23
EP1100538A4 (en) 2003-07-02
US6420124B1 (en) 2002-07-16
WO2000006199A1 (en) 2000-02-10

Similar Documents

Publication Publication Date Title
EP1100825A4 (en) HUMAN MINK GENE MUTATIONS RELATED TO ARRHYTMIA
Burwinkel et al. Unequal homologous recombination between LINE-1 elements as a mutational mechanism in human genetic disease
Heath et al. Low-density lipoprotein receptor gene (LDLR) world-wide website in familial hypercholesterolaemia: update, new features and mutation analysis
Yamada et al. A comprehensive analysis of allelic methylation status of CpG islands on human chromosome 21q
Morris et al. Family-based association mapping provides evidence for a gene for reading disability on chromosome 15q
Gad et al. Identification of a large rearrangement of theBRCA1 gene using colour bar code on combed DNA in an American breast/ovarian cancer family previously studied by direct sequencing
Lucas et al. Desmoid tumor is a clonal cellular proliferation: PCR amplification of HUMARA for analysis of patterns of X-chromosome inactivation
FR2731014B1 (fr) Molecules d'adn, preparation et utilisation en therapie genique
EP0961833A4 (en) HYALURONIDASE FROM HUMAN PLASMA
Nakashima et al. The combination of polymorphisms within interferon‐γ receptor 1 and receptor 2 associated with the risk of systemic lupus erythematosus
ATE369420T1 (de) Kvlqt1 - im zusammenhang mit 'long qt syndrom'
EP1553190A3 (en) Mutations in and genomic structure of HERG - a long QT syndrome gene
Takada et al. Female agammaglobulinemia due to the Bruton tyrosine kinase deficiency caused by extremely skewed X-chromosome inactivation
EP0973794A4 (en) NETRIN RECEPTORS
WO2000063441A3 (en) Single nucleotide polymorphisms in mitochondrial genes that segregate with alzheimer's disease
Lovell et al. Ethiopia: between sub‐Saharan Africa and western Eurasia
Park et al. Human chromosome 9 pericentric homologies: implications for chromosome 9 heteromorphisms
Zahedi et al. Transcriptional regulation of the C1 inhibitor gene by gamma-interferon
Putku et al. Novel polymorphic AluYb8 insertion in the WNK1 gene is associated with blood pressure variation in Europeans
Nakatsuru et al. Genetic dissection of the complex pathological manifestations of collagen disease in MRL/lpr mice
Gasser et al. P1 and cosmid clones define the organization of 280 kb of the mouse H-2 complex containing the Cps-1 and Hsp70 loci
Onodera et al. High prevalence of spinocerebellar ataxia type 1 (SCA1) in an isolated region of Japan
Boehm et al. Use of oligonucleotide hybridization in the characterization of a β-thalassemia gene (β37 TGG→ TGA) in a Saudi Arabian family
Calvo et al. Characterization, genetic variation and chromosomal assignment to sheep chromosome 2 of the ovine heart fatty acid-binding protein gene (FABP3)
ATE464318T1 (de) Gen das in schizophrenie defekt ist

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties